Aggressive Non-Hodgkin Lymphoma — Trials

Aggressive Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

648 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 182
Recruiting: 92
Ph III recruiting: 4
Growth YoY: +6.7%
Industry share: 18%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (109)

clinicaltrialsPublishedShowing 101–150 of 340 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06834373	Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy	recruiting	Phase 2	41	Mayo ClinicOTHER	1	Jan 28, 2026	clinicaltrials
NCT06575686	Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma	suspended	Phase 2	33	City of Hope Medical CenterOTHER	1	Jan 21, 2026	clinicaltrials